Categories AlphaGraphs, Earnings, Health Care

Earnings: AngioDynamics (ANGO) reports higher adj. profit for Q4; revenue up 5%

Medical device company AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported an increase in adjusted profit for the fourth quarter of 2023, aided by a 5% growth in revenues. The company also provided guidance for fiscal 2024.

AngioDynamics Q4 2023 earnings infographic

Earnings, excluding special items, edged up to $0.02 per share in the May quarter from $0.01 per share in the same period of 2022. On an unadjusted basis, it was a net loss of $21.5 million or $0.54 per share, compared to a loss of $6.27 million or $0.16 per share in the prior-year quarter.

Fourth-quarter revenues increased 5% year-over-year to $91.1 million. The company expects fiscal 2024 revenues to be in the range of $328 million to $333 million.

Commenting on the results, AngioDynamics’ CEO Jim Clemmer said, “Looking ahead, we will continue to seek opportunities to further focus the portfolio in order to drive growth and margin expansion.”

Prior Performance

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Viewing Highlight